PLX8394 - Raf 抑制劑 - 生命科學試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPLX8394Cat. No.: HY-18972CAS No.: 1393466-87-9分式: CHFNOS分量: 542.53作靶點: Raf作通路: MAPK/ERK Pathway儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 39 mg/mL (71.89 mM)H2O : 40% PEG300 5% Tween-8

2、0 45% salineSolubility: 2.08 mg/mL (3.83 mM); Clear solutionBIOLOGICAL ACTIVITY1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 PLX8394種有效的，選擇性的 BRaf 抑制劑，抑制 BRAFV600E 活性的 IC50 值約為 5 nM。IC50 & Target BRafV600E5 nM (IC50)體外研究 PLX8394 potently inhibits phosphorylation of ERK1/2 in PRT #3 and PRT #4

3、 cells at 25 nM and in additionto parental cells at 10 nM. PLX8394 effectively reduces cyclin D3 and cyclin D1, phosphorylation ofretinoblastoma protein, and expression of cyclin A2 in parental cells and PRT #3 and PRT #4 cells. PLX8394inhibits ERK1/2 phosphorylation and the growth of vemurafenib-re

4、sistant cells harboring either a BRAFV600K/L505H double mutation or an transposon-induced, N-terminal truncated form of BRAF 1. PLX8394significantly impairs tumor cell growth and suppresses MAPK signaling in LA cell lines expressing eitherendogenous V600E or non-V600 mutant forms of BRAF 2.體內研究 PLX8

5、394 (150 mg/kg/d) substantially suppresses tumor growth, MAPK pathway signaling and tumor cellproliferation in these H1755 xenograft tumors without overt toxicity in mice. PLX8394 combines with erlotinibyields plasma erlotinib concentrations of 1 M 2.PROTOCOLCell Assay 1 For MTT assays, 2103 cells a

6、re seeded in triplicate in 96 wells in their regular culture medium (containingPLX4720 for PRT lines). Next day, cells are washed twice with PBS and then the medium is replenishedcontaining the indicated RAF inhibitor. Medium is changed 48 hours later and after a further 48 hours, 10 Lof 5 mg/mL MTT

7、 reagent is added to wells, and incubated for three hours. Formazan crystals are thensolubilized overnight with a 1:10 dilution of 0.1 M glycine (pH 10.5) in DMSO. Wells are then analyzed at 450nM in a Multiskan Spectrum spectrophotometer. Results depicted are normalized to DMSO conditions andare a

8、composite of three independent experiments. Error bars shown are representative of the standard errorof mean (SEM).MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal H1755 tumor xenografts are generated by injection of 5106 cells in a 50/50 mixture

9、for matrigel and PBSAdministration 2 into 6- to 8-wk-old female NOD/SCID mice. Mice are randomized to treatment groups once tumors reach anaverage size of 150 mm3. H1755 cells are s.c. implanted and allowed to grow to appr 200 mm3 (4 wk afterimplantation). Mice are then treated with vehicle, vemuraf

10、enib, or PLX8394 for 15 d. The vehicle for daily oralgavage is PEG 400 20% (vol/vol), tocopheryl polyethylene glycol succinate (TPGS) 5% (vol/vol), water75% (vol/vol). PLX8394 is dissolved in PEG 400 20% (vol/vol), TPGS 5% (vol/vol), and water 75%(vol/vol) and vortexed continuously throughout the do

11、sing period. PLX8394 is given daily by oral gavage at adose of 150 mg/kg/d.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻 Cancer Discov. 2018 Sep;8(9):1130-1141. Nat Commun. 2018 Nov 14;9(1):4775.2/3 Master of Small Molecules 您邊的抑制劑師www.Med

12、ChemE Clin Sci (Lond). 2019 Apr 16;133(8):919-932. Mol Cell Biol. 2016 Sep 26;36(20):2612-25.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Basile KJ, et al. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell MelanomaRes. 2014 May;27(3):479-484.2. Okimoto RA, et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461McePdfHeig